Lunai Bioworks (LNAI) Change in Account Payables (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Change in Account Payables of $639638.0 for Q1 2026, down 19.19% year-over-year from $791503.0 in Q1 2025, and up 160.87% quarter-over-quarter from $245191.0 in Q4 2025.
Lunai Bioworks (LNAI) Change in Account Payables (2011 - 2026) Analysis & Trends
Lunai Bioworks' Change in Account Payables history runs 15 years deep, the most recent figure standing at $639638.0 for Q1 2026.
- In Q1 2026, Change in Account Payables fell 19.19% year-over-year to $639638.0; the TTM figure through Mar 2026 stood at $2.2 million (down 46.84% YoY), while the FY2025 annual figure was $3.1 million, down 23.44% from the prior year.
- Change in Account Payables for Q1 2026 stood at $639638.0, up from $245191.0 in the prior quarter.
- The five-year high for Change in Account Payables was $3.3 million in Q3 2022, with the low at -$467667.0 in Q4 2024.
- The 5-year median for Change in Account Payables is $639638.0 (2026), against an average of $806504.2.
- Peak annual rise in Change in Account Payables reached 2280.89% in 2024, while the deepest fall reached 398.27% in 2024.
- Lunai Bioworks' Change in Account Payables stood at -$127519.0 in 2022, then soared by 222.96% to $156792.0 in 2023, then tumbled by 398.27% to -$467667.0 in 2024, then jumped by 152.43% to $245191.0 in 2025, then soared by 160.87% to $639638.0 in 2026.
- Business Quant data shows LNAI's Change in Account Payables at $639638.0 in Q1 2026, $245191.0 in Q4 2025, and $532206.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 639,638.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 639,638.00 |
| Mar 31, 2026 | 639,638.00 |
| Dec 31, 2025 | 245,191.00 |
| Dec 31, 2025 | 245,191.00 |
| Sep 30, 2025 | 532,206.00 |
| Sep 30, 2025 | 532,206.00 |
| Jun 30, 2025 | 828,806.00 |
| Jun 30, 2025 | 828,806.00 |
| Mar 31, 2025 | 791,503.00 |
| Mar 31, 2025 | 791,503.00 |
| Dec 31, 2024 | -467,667.00 |
| Dec 31, 2024 | -467,667.00 |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | 1.83 Mn |
| Mar 31, 2024 | 1.83 Mn |
| Dec 31, 2023 | 156,792.00 |
| Dec 31, 2023 | 156,792.00 |